Search
Stannous fluoride
go.drugbank.com/drugs/DB11092ApprovedInvestigationalIt is an FDA-approved over-the-counter product.
Triflusal
go.drugbank.com/drugs/DB08814ApprovedWithdrawnThe benefits of this agent are the lack of action over the arachidonic acid pathway, the driven production of nitric oxide and the increase of cyclic nucleotide concentration on endothelial cells.
Omadacycline
go.drugbank.com/drugs/DB12455ApprovedInvestigationalOmadacycline represents a significant advance over the well-known tetracycline family, and has been shown to be highly effective in animal models at treating increasingly problematic, clinically prevalent
Categories: P-glycoprotein substratesKD7040
go.drugbank.com/drugs/DB05214InvestigationalKD7040 is a topically-delivered inducible nitric oxide synthase (iNOS) inhibitor for the treatment of neuropathic pain. The KD7040 IND was filed in 4Q06, and a Phase Ib clinical trial began 2Q07. It is being developed by Kalypsys.
PF-00217830
go.drugbank.com/drugs/DB12998InvestigationalPF-00217830 has been used in trials studying the treatment of Schizophrenia.
Fexofenadine
go.drugbank.com/drugs/DB00950ApprovedInvestigationalFexofenadine is an over-the-counter second-generation antihistamine used in the treatment of various allergic symptoms.
Categories: P-glycoprotein substratesProducts: ALERMED® 30 MG/5 ML, Telfast Oral Suspension 6 mg/mlVaricella zoster vaccine (recombinant)
go.drugbank.com/drugs/DB13924ApprovedInvestigationalThere are numerous advantages to using Shingrix over Zostavax. … Efficacy of Zostavax also wanes over time, with protection against shingles and PHN lasting only around 5 years.
Helium
go.drugbank.com/drugs/DB09155ApprovedInvestigationalVet approvedHelium is a second most abundant chemical element in the universe with symbol He and atomic number 2. It is a colorless, odorless, tasteless, non-toxic, inert, monatomic gas located at the top of the noble gases on the periodic table. It...
Nurulimab
go.drugbank.com/drugs/DB18946InvestigationalNurulimab is under investigation in clinical trial NCT05732805 (A Clinical Study of BCD-217 (Nurulimab + Prolgolimab) Followed by Anti-pd-1 Compared to Anti-pd-1 Monotherapy as First-line Treatment in
Peginterferon alfa-2a
go.drugbank.com/drugs/DB00008ApprovedInvestigationalPeginterferon alfa-2a is a form of recombinant interferon used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). HCV is a single-stranded RNA virus ...
Categories: Cytochrome P-450 CYP1A2 Inhibitors, Cytochrome P-450 Enzyme InhibitorsProducts: PEGASYS PRE-FILLED SYRINGE FOR INJECTION 180 mcg/0.5 ml, PEGASYS PRE-FILLED SYRINGE FOR INJECTION 135 mcg/0.5 ml